Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Net Cash Flow (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Net Cash Flow for 11 consecutive years, with -$18.3 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 177.74% to -$18.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$87.4 million through Dec 2025, down 164.3% year-over-year, with the annual reading at -$87.4 million for FY2025, 164.3% down from the prior year.
  • Net Cash Flow for Q4 2025 was -$18.3 million at Cartesian Therapeutics, down from -$16.9 million in the prior quarter.
  • The five-year high for Net Cash Flow was $132.0 million in Q3 2024, with the low at -$34.0 million in Q3 2023.
  • Average Net Cash Flow over 5 years is -$658900.0, with a median of -$8.8 million recorded in 2021.
  • Peak annual rise in Net Cash Flow hit 7416.87% in 2022, while the deepest fall reached 992.78% in 2022.
  • Over 5 years, Net Cash Flow stood at -$582000.0 in 2021, then tumbled by 992.78% to -$6.4 million in 2022, then soared by 57.42% to -$2.7 million in 2023, then crashed by 142.73% to -$6.6 million in 2024, then crashed by 177.74% to -$18.3 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$18.3 million, -$16.9 million, and -$20.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.